Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
09:15am, Monday, 29'th Sep 2025
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clin
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
10:15am, Sunday, 28'th Sep 2025
Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incr
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regai
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
04:21am, Friday, 26'th Sep 2025
Eli Lilly (LLY -3.77%) recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's (NVO -4.54%) oral version of Wegovy (semaglutide),
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
07:02am, Monday, 22'nd Sep 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancem
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
11:55am, Friday, 19'th Sep 2025
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
11:20am, Friday, 19'th Sep 2025
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy Kelowna, British Columbia – September 19, 2025 – TheNewswire - Lexaria Bioscience Corp. (Na
Eli Lilly's Oral GLP-1 Breakthrough Could Change Everything
03:25pm, Thursday, 18'th Sep 2025
Eli Lilly and Company NYSE: LLY has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, whi
Is Global Partners (GLP) Stock Outpacing Its Oils-Energy Peers This Year?
10:41am, Thursday, 18'th Sep 2025
Here is how Global Partners LP (GLP) and Siemens Energy AG Unsponsored ADR (SMNEY) have performed compared to their sector so far this year.
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:41am, Thursday, 18'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
09:45am, Thursday, 18'th Sep 2025
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
06:14pm, Wednesday, 17'th Sep 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week exten
Lilly's GLP-1 Pill Outperforms Older Novo Drug
10:39am, Wednesday, 17'th Sep 2025
Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial
Lilly's GLP-1 pill seen as superior in head-to-head trial with Novo's oral semaglutide
10:28am, Wednesday, 17'th Sep 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details about Eli Lilly's new drug trial.
